Latest On Cellectis S.A (CLLS):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-05 22:51 EST | News | Cellectis SA (CLLS) Q1 2023 Earnings Call Transcript | N/A |  |
| 2023-05-04 21:01 EST | News | Cellectis Non-GAAP EPS of -$0.55 misses by $0.13, revenue of $3.56M misses by $2.54M | N/A | |
| 2023-05-03 19:43 EST | News | Cellectis Q1 2023 Earnings Preview | N/A | |
| 2023-03-09 11:40 EST | News | Cellectis S.A. (CLLS) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-03-08 21:01 EST | News | Cellectis GAAP EPS of -$0.02 beats by $0.58, revenue of $17.32M misses by $4.93M | N/A | |
| 2023-02-03 17:08 EST | News | Cellectis shares dip on pricing follow-on offering at $2.50/ADS | N/A | |
| 2023-02-03 03:45 EST | News | Cellectis stock plunges ~17% after hours on $22M ADS offering | N/A | |
| 2023-01-23 11:16 EST | News | Cellectis rises as terms of Cytovia licensing deal change | N/A | |
| 2023-01-17 16:20 EST | News | Calyxt surges on merger with agriculture gene editing company Cibus | N/A | |
| 2022-12-30 03:56 EST | News | Cellectis, Primera Therapeutics to develop therapies for mitochondrial diseases | N/A | |
| 2022-12-28 22:50 EST | News | Cellectis to get €40M from European Investment Bank to support CAR T-cell development | N/A | |
| 2022-11-05 06:46 EST | News | Cellectis S.A. (CLLS) Q3 2022 Earnings Call Transcript | N/A | |
| 2022-11-03 21:20 EST | News | Cellectis GAAP EPS of -$0.63 misses by $0.14, revenue of $1.92M | N/A | |
| 2022-11-03 04:04 EST | News | Cellectis Q3 2022 Earnings Preview | N/A | |
| 2022-08-06 04:34 EST | News | Cellectis S.A. (CLLS) CEO Andre Choulika on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-08-04 22:01 EST | News | Cellectis Non-GAAP EPS of -$0.36 beats by $0.21, revenue of $2.76M | N/A | |
| 2022-08-04 06:27 EST | News | Cellectis Q2 2022 Earnings Preview | N/A | |
| 2022-08-01 20:41 EST | News | FDA clears Cellectis' investigational new drug application for lymphoma treatment | N/A | |
| 2022-05-14 08:53 EST | News | Cellectis S.A.'s (CLLS) CEO Andre Choulika on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-05-13 05:44 EST | News | Cellectis Non-GAAP EPS of -$0.64 beats by $0.02, revenue of $3.83M misses by $14.68M | N/A | |
| 2022-05-12 10:31 EST | News | Cellectis Q1 2022 Earnings Preview | N/A | |
| 2022-03-12 00:25 EST | News | Cellectis rides on FDA’s Fast Track tag for Allogene’s CAR-T therapy | N/A | |
| 2022-03-04 17:00 EST | News | Cellectis S.A. (CLLS) CEO Andre Choulika on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-03-03 23:29 EST | News | Cellectis GAAP EPS of -$0.18, revenue of $1.94M | N/A | |
| 2022-03-03 05:59 EST | News | Cellectis Q4 2021 Earnings Preview | N/A | |
| 2022-02-10 21:27 EST | News | Cellectis ropes in biotech veteran Bing Wang as CFO | N/A | |
| 2021-11-05 19:16 EST | News | Cellectis S.A. (CLLS) CEO Andre Choulika on Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2021-11-04 22:59 EST | News | Cellectis EPS beats by $0.04, beats on revenue | N/A | |
| 2021-11-04 01:41 EST | News | Cellectis Q3 2021 Earnings Preview | N/A | |
| 2021-10-20 00:29 EST | News | Cellectis highlights preclinical data to be presented for two gene therapies | N/A | |
| 2021-10-12 18:39 EST | News | Warning: CLLS is at high risk of performing badly | N/A | |
| 2021-10-09 15:29 EST | News | Xenon Pharma, ChemoCentryx lead weekly healthcare gainers; Prelude, Allogene trail | N/A | |
| 2021-10-08 20:59 EST | News | Allogene study halt drags down peers on safety concerns | N/A | |
| 2021-10-08 01:15 EST | News | MNTV, AUTL, ALLO and CLLS among after hours movers | N/A | |
| 2021-10-07 01:56 EST | News | CLLS is at high risk of performing badly | N/A | |
| 2021-09-27 10:18 EST | News | Warning: CLLS has been downgraded to Very Bearish | N/A | |
| 2021-09-22 17:47 EST | News | Warning: CLLS has been downgraded to Very Bearish. | N/A | |
| 2021-08-06 16:58 EST | News | Cellectis S.A. (CLLS) CEO André Choulika on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-08-05 19:54 EST | News | Cellectis EPS misses by $0.28, beats on revenue | N/A | |
| 2021-07-22 16:15 EST | News | Cellectis outlines four new UCART preclinical programs; reveals .HEAL, a genome surgery platform | N/A | |
| 2021-07-22 16:14 EST | News | Cellectis: FYE 2021 TALEN CAR-T Data Announcement Should Catalyse Strong Upside | N/A | |
| 2021-07-22 16:12 EST | News | Cellectis Offers An Idiosyncratic Risk Profile With Remarkable Upside Potential | N/A | |
| 2021-05-07 01:32 EST | News | Cellectis EPS beats by $0.52, beats on revenue | N/A | |
| 2021-04-09 16:18 EST | News | Cellectis finalizes of $47M through ATM program | N/A | |
| 2021-03-17 16:19 EST | News | Biogen expected to receive FDA nod for Alzheimer’s therapy and Solid Bioscience upgraded in today’s analyst action | N/A | |
| 2021-03-17 15:26 EST | Analyst Rating | The Analyst Target Price has increased from $33 to $34.6. | Buy | |
| 2021-03-09 02:22 EST | Analyst Rating | The Analyst Target Price has decreased from $33.9 to $33. | Neutral | |
| 2021-03-08 13:55 EST | Analyst Rating | The Analyst Target Price has decreased from $35.1 to $33.9. | Neutral | |
| 2021-03-08 13:55 EST | Earnings Estimate | An EPS average of -$3.33 is estimated for the 2022 year. | Sell | |
| 2021-03-08 13:55 EST | Earnings Estimate | An EPS average of -$0.50 is estimated for the quarter ending on June 30, 2021. | Buy | |
About Cellectis S.A (CLLS):
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. The company was founded in 1999 and is headquartered in Paris, France.
General
- Name Cellectis S.A
- Symbol CLLS
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 272
- Fiscal Year EndDecember
- IPO Date2007-02-07
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.cellectis.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 11.57
- Price/Book (Most Recent Quarter) 3.13
- Enterprise Value Revenue 9.98
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$2.55
- Next Year EPS Estimate -$2.96
- Next Quarter EPS Estimate -$0.72
- Profit Margin -98%
- Operating Margin -103%
- Return on Assets -11%
- Return on Equity -29%
- Revenue 82.46 million
- Earnings Per Share -$2.24
- Revenue Per Share $1.94
- Gross Profit 46.18 million
- Quarterly Earnings Growth 150.7%
View More
Highlights
- Market Capitalization 875.72 million
- EBITDA -115498000
- Analyst Target Price $34.6
- Book Value Per Share $6.44
View More
Share Statistics
- Shares Outstanding 42.78 million
- Shares Float 28.02 million
- % Held by Insiders <1%
- % Held by Institutions 33.88%
- Shares Short 866798
- Shares Short Prior Month 397982
- Short Ratio 1.82
- Short % of Shares Outstanding 2%
View More
Technicals
- Beta 2.19
- 52 Week High $34.71
- 52 Week Low $7.55
- 50 Day Moving Average 23.78
- 200 Day Moving Average 22.99
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Cellectis S.A (CLLS) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Cellectis S.A (CLLS) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-03-04 | $N/A | -$0.95 | -$0.80 | -18.38% |
| 2020-09-30 | 2020-11-05 | $6.18 million | -$0.71 | -$0.61 | -15.77% |
| 2020-06-30 | 2020-08-05 | $N/A | -$0.76 | -$0.74 | -2.7% |
| 2020-03-31 | 2020-05-06 | $N/A | $0.47 | -$0.65 | 172.43% |
| 2019-12-31 | 2020-03-04 | $4.42 million | -$0.88 | -$0.74 | -19.73% |
| 2019-09-30 | 2019-11-06 | $8.49 million | -$0.38 | -$0.80 | 52.74% |
| 2019-06-30 | 2019-08-06 | $1.15 million | -$0.79 | -$0.60 | -31.67% |
| 2019-03-31 | 2019-05-07 | $1.04 million | -$0.36 | -$0.66 | 45.45% |
| 2018-12-31 | 2019-03-11 | $2.98 million | -$0.53 | -$0.72 | 26.53% |
| 2018-09-30 | 2018-11-13 | $2.19 million | -$0.54 | -$0.59 | 8.47% |
| 2018-06-30 | 2018-08-01 | $8.34 million | -$0.17 | -$0.58 | 70.76% |
| 2018-03-31 | 2018-05-07 | $8.07 million | -$0.71 | -$0.62 | -13.91% |
| 2017-12-31 | 2018-03-12 | $5.73 million | -$0.76 | -$0.68 | -11.63% |
| 2017-09-30 | 2017-11-13 | $5.51 million | -$0.73 | -$0.58 | -26.96% |
| 2017-06-30 | 2017-08-02 | $7.19 million | -$0.81 | -$0.59 | -37.7% |
| 2017-03-31 | 2017-05-09 | $6.77 million | -$0.58 | -$0.61 | 6.12% |
| 2016-12-31 | 2017-03-06 | $5.76 million | -$0.37 | -$0.34 | -9.62% |
| 2016-09-30 | 2016-11-22 | $11.81 million | -$0.38 | -$0.63 | 39.65% |
| 2016-06-30 | 2016-09-08 | $17.21 million | -$0.20 | -$0.42 | 51.23% |
| 2016-03-31 | 2016-05-11 | $7.95 million | -$0.96 | -$0.51 | -90% |
| 2015-12-31 | 2016-03-14 | $28.6 million | $0.26 | $0.24 | 4.71% |
| 2015-09-30 | 2015-11-19 | $8.5 million | -$0.40 | -$0.30 | -33.33% |
| 2015-06-30 | 2015-09-09 | $8.52 million | -$0.63 | -$0.36 | -75% |
| 2015-03-31 | 2015-06-09 | $9.05 million | $0.26 | -$0.04 | 750% |
Cellectis S.A (CLLS) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Cellectis S.A (CLLS) Chart:
Cellectis S.A (CLLS) News:
Below you will find a list of latest news for Cellectis S.A (CLLS) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Cellectis S.A (CLLS) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2025-11-21 | 2.5 | 2 | CALL | 0 | 498 | 0 | TRUE | 0 | 0 |
| 2025-11-21 | 5 | 0.25 | CALL | 2 | 290 | 205.49 | FALSE | 0.25 | 0 |
| 2025-11-21 | 7.5 | 0.15 | CALL | 37 | 79 | 262.62 | FALSE | 0.15 | 0 |
| 2025-11-21 | 2.5 | 0.1 | PUT | 0 | 61 | 841.9 | FALSE | 0 | 0 |
| 2025-11-21 | 5 | 1.5 | PUT | 0 | 2 | 322.89 | TRUE | 0 | 0 |
| 2025-11-21 | 7.5 | 0 | PUT | 0 | 0 | 358.16 | TRUE | 0 | 0 |
| 2025-12-19 | 2.5 | 0 | CALL | 0 | 0 | 192.5 | TRUE | 0 | 0 |
| 2025-12-19 | 5 | 0.7 | CALL | 0 | 31 | 449.39 | FALSE | 0 | 0 |
| 2025-12-19 | 7.5 | 0 | CALL | 0 | 0 | 471.16 | FALSE | 0 | 0 |
| 2025-12-19 | 2.5 | 0 | PUT | 0 | 0 | 652.95 | FALSE | 0 | 0 |
| 2025-12-19 | 5 | 1.8 | PUT | 0 | 2 | 148.17 | TRUE | 0 | 0 |
| 2025-12-19 | 7.5 | 0 | PUT | 0 | 0 | 161.42 | TRUE | 0 | 0 |
| 2026-02-20 | 2.5 | 2.1 | CALL | 0 | 41 | 203.9 | TRUE | 0 | 0 |
| 2026-02-20 | 5 | 0.45 | CALL | 0 | 288 | 184.12 | FALSE | 0 | 0 |
| 2026-02-20 | 7.5 | 0.55 | CALL | 1 | 14 | 133.37 | FALSE | 0.55 | 0 |
| 2026-02-20 | 2.5 | 0.95 | PUT | 0 | 13 | 549.58 | FALSE | 0 | 0 |
| 2026-02-20 | 5 | 1.5 | PUT | 0 | 26 | 131.08 | TRUE | 0 | 0 |
| 2026-02-20 | 7.5 | 4.8 | PUT | 0 | 1 | 116.94 | TRUE | 0 | 0 |
| 2026-05-15 | 2.5 | 2.2 | CALL | 0 | 20 | 213.83 | TRUE | 0 | 0 |
| 2026-05-15 | 5 | 0.95 | CALL | 0 | 7 | 113.17 | FALSE | 0 | 0 |
| 2026-05-15 | 7.5 | 0.6 | CALL | 0 | 18 | 317.69 | FALSE | 0 | 0 |
| 2026-05-15 | 2.5 | 0.45 | PUT | 0 | 21 | 0 | FALSE | 0 | 0 |
| 2026-05-15 | 5 | 1.68 | PUT | 0 | 0 | 108.77 | TRUE | 0 | 0 |
| 2026-05-15 | 7.5 | 0 | PUT | 0 | 0 | 102.78 | TRUE | 0 | 0 |
Latest CLLS Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:51 PM EST | 80 | $2.42 |
| Jun 13, 2022 7:52 PM EST | 17 | $2.415 |
| Jun 13, 2022 7:52 PM EST | 5 | $2.41 |
| Jun 13, 2022 7:52 PM EST | 20 | $2.42 |
| Jun 13, 2022 7:52 PM EST | 80 | $2.43 |
Cellectis S.A (CLLS) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000119312520183336/0001193125-20-183336-index.htm |
| 2019-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1627281/000031506619000953/0000315066-19-000953-index.htm |
| 2020-02-07 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1627281/000031506620000868/0000315066-20-000868-index.htm |
| 2020-10-20 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1627281/000089924320028665/0000899243-20-028665-index.htm |
| 2020-08-04 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1627281/000110465920090155/0001104659-20-090155-index.htm |
| 2018-11-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000115752318002419/0001157523-18-002419-index.htm |
| 2018-12-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000115752318002551/0001157523-18-002551-index.htm |
| 2019-02-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000115752319000441/0001157523-19-000441-index.htm |
| 2019-03-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000115752319000555/0001157523-19-000555-index.htm |
| 2019-04-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000115752319000730/0001157523-19-000730-index.htm |
| 2019-04-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000115752319000832/0001157523-19-000832-index.htm |
| 2019-05-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000115752319001127/0001157523-19-001127-index.htm |
| 2019-07-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000115752319001506/0001157523-19-001506-index.htm |
| 2019-08-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000115752319001730/0001157523-19-001730-index.htm |
| 2019-10-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000115752319002025/0001157523-19-002025-index.htm |
| 2019-10-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000115752319002121/0001157523-19-002121-index.htm |
| 2019-11-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000115752319002210/0001157523-19-002210-index.htm |
| 2019-11-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000115752319002263/0001157523-19-002263-index.htm |
| 2019-11-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000115752319002294/0001157523-19-002294-index.htm |
| 2019-12-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000115752319002313/0001157523-19-002313-index.htm |
| 2020-01-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000115752320000019/0001157523-20-000019-index.htm |
| 2020-01-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000115752320000058/0001157523-20-000058-index.htm |
| 2020-01-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000115752320000069/0001157523-20-000069-index.htm |
| 2020-02-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000115752320000217/0001157523-20-000217-index.htm |
| 2020-02-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000115752320000264/0001157523-20-000264-index.htm |
| 2020-03-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000115752320000297/0001157523-20-000297-index.htm |
| 2020-03-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000115752320000300/0001157523-20-000300-index.htm |
| 2020-03-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000115752320000324/0001157523-20-000324-index.htm |
| 2020-04-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000117184320002573/0001171843-20-002573-index.htm |
| 2020-04-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000117184320003030/0001171843-20-003030-index.htm |
| 2020-05-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000117184320003376/0001171843-20-003376-index.htm |
| 2020-05-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000117184320003812/0001171843-20-003812-index.htm |
| 2020-06-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000117184320004568/0001171843-20-004568-index.htm |
| 2020-06-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000117184320004619/0001171843-20-004619-index.htm |
| 2020-07-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000117184320004765/0001171843-20-004765-index.htm |
| 2020-07-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000117184320004770/0001171843-20-004770-index.htm |
| 2020-07-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000117184320005067/0001171843-20-005067-index.htm |
| 2020-08-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000117184320005556/0001171843-20-005556-index.htm |
| 2020-10-16 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000117184320007069/0001171843-20-007069-index.htm |
| 2020-11-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000117184320007541/0001171843-20-007541-index.htm |
| 2020-11-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000117184320007688/0001171843-20-007688-index.htm |
| 2018-10-05 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1627281/000119312518294687/0001193125-18-294687-index.htm |
| 2018-11-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000119312518325318/0001193125-18-325318-index.htm |
| 2019-03-12 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000119312519071066/0001193125-19-071066-index.htm |
| 2019-03-12 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1627281/000119312519071189/0001193125-19-071189-index.htm |
| 2019-04-25 | 20-F/A | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1627281/000119312519118247/0001193125-19-118247-index.htm |
| 2019-05-03 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000119312519137013/0001193125-19-137013-index.htm |
| 2019-05-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000119312519139951/0001193125-19-139951-index.htm |
| 2019-06-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000119312519182674/0001193125-19-182674-index.htm |
| 2019-08-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000119312519214113/0001193125-19-214113-index.htm |
| 2019-09-23 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1627281/000119312519251590/0001193125-19-251590-index.htm |
| 2019-11-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000119312519285998/0001193125-19-285998-index.htm |
| 2020-03-05 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1627281/000119312520061833/0001193125-20-061833-index.htm |
| 2020-05-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000119312520134950/0001193125-20-134950-index.htm |
| 2020-05-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000119312520137609/0001193125-20-137609-index.htm |
| 2020-06-02 | F-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers | https://www.sec.gov/Archives/edgar/data/1627281/000119312520158486/0001193125-20-158486-index.htm |
| 2020-06-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000119312520183336/0001193125-20-183336-index.htm |
| 2020-07-10 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1627281/000119312520190839/0001193125-20-190839-index.htm |
| 2020-08-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000119312520210738/0001193125-20-210738-index.htm |
| 2020-09-09 | 6-K/A | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000119312520241954/0001193125-20-241954-index.htm |
| 2020-10-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000119312520261294/0001193125-20-261294-index.htm |
| 2020-10-16 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000119312520271088/0001193125-20-271088-index.htm |
| 2020-10-23 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1627281/000119312520275427/0001193125-20-275427-index.htm |
| 2020-11-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000119312520286842/0001193125-20-286842-index.htm |
| 2020-11-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1627281/000119312520286910/0001193125-20-286910-index.htm |
| 2018-10-15 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1627281/000119380518001224/0001193805-18-001224-index.htm |
| 2020-02-14 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1627281/000156223020000007/0001562230-20-000007-index.htm |